[
    [
        {
            "time": "",
            "original_text": "贝达药业贝伐珠单抗注射液（贝安汀?）新增四项适应症申请获受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "贝伐珠单抗",
                    "注射液",
                    "贝安汀",
                    "新增",
                    "适应症",
                    "申请",
                    "受理"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业贝伐珠单抗注射液（贝安汀?）新增四项适应症申请获受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "喜讯！贝达药业荣获“2021年浙江本土民营跨国公司经营50强”",
            "features": {
                "keywords": [
                    "贝达药业",
                    "喜讯",
                    "荣获",
                    "2021年",
                    "浙江",
                    "本土",
                    "民营",
                    "跨国公司",
                    "经营50强"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "喜讯！贝达药业荣获“2021年浙江本土民营跨国公司经营50强”",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：贝伐珠单抗注射液（贝安汀）新增适应症补充申请获得受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "贝伐珠单抗",
                    "注射液",
                    "贝安汀",
                    "新增",
                    "适应症",
                    "补充",
                    "申请",
                    "受理"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：贝伐珠单抗注射液（贝安汀）新增适应症补充申请获得受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]